Novonesis dans l'actualité
Solutions biologiques pour la durabilité
Tamtam a trouvé 20 articles récents sur Novonesis.
- Novonesis' bid for Microbiogen under review in Australia
- SEB raises Novonesis price target to 560 Danish kroner (545), reiterates buy
- Efficiency and sustainability go hand in hand in modern poultry production | Novonesis
- Novonesis raises 2026 outlook as first-half sales jump 8%
- The science of HMOs – A novonesis webinar featuring new clinical findings and ESPGHAN highlights
- Novonesis Jumps as High-Protein Demand Helps Fuel Buyback
- Novonesis shares jump 9% after Q2 beat, raised 2026 sales guidance, buyback
- Novonesis CEO: Earnings put us in a good place
- Novonesis Expects Results From Weight-Loss Drug Supplement Study in 2027
- Earnings call transcript: Novonesis raises 2026 outlook as shares jump 8.5%
- Morgan Stanley raises the price target for Novonesis to 535 Danish kroner (520), reiterates overweight - BN
- Novonesis expects results from weight-loss drug supplement study in 2027
- Novonesis Shares Jump as High Protein Demand Enables Buyback
- Novonesis Leads Europe’s Stoxx 600 on Sales Beat, Guidance Raise
- Novonesis H1 2026 Results: Organic sales up 8%, raises outlook
- Novonesis Approves EUR 1 Billion Share Buyback Program To Start In H2 2026
- Novonesis Says Outlook For FY Adjusted EBITDA Margin Is Now 37-38%
- H1 2026: Novonesis delivered strong 8% organic sales growth and increases full-year outlook
- Novonesis to roll out ₹3,000-crore Maharashtra investment over next 24-36 months
- DNB Carnegie raises the target price for Novonesis to 470 Danish kroner (450), reiterates buy
Articles collectés par Tamtam et retenus lorsqu'ils portent sur l'entreprise, des plus récents aux plus anciens. Chacun renvoie à sa source.
Vous vendez à des entreprises comme Novonesis ?
Tamtam trouve les entreprises qui correspondent à votre client idéal, analyse chaque compte et vous dit qui contacter, et quand.
Trouver des entreprises similaires